These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 34718178)
1. A nanotherapeutic strategy to overcome chemoresistance to irinotecan/7-ethyl-10-hydroxy-camptothecin in colorectal cancer. Huang Q; Liu X; Wang H; Liu X; Zhang Q; Li K; Chen Y; Zhu Q; Shen Y; Sui M Acta Biomater; 2022 Jan; 137():262-275. PubMed ID: 34718178 [TBL] [Abstract][Full Text] [Related]
2. Characterization of SN38-resistant T47D breast cancer cell sublines overexpressing BCRP, MRP1, MRP2, MRP3, and MRP4. Lee HJ; Choi CH BMC Cancer; 2022 Apr; 22(1):446. PubMed ID: 35461219 [TBL] [Abstract][Full Text] [Related]
3. Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors. Nguyen F; Guan P; Guerrero DT; Kolla V; Naraparaju K; Perry LM; Soberman D; Pressly BB; Alferiev IS; Chorny M; Brodeur GM Cancer Res; 2020 Oct; 80(19):4258-4265. PubMed ID: 32839252 [TBL] [Abstract][Full Text] [Related]
4. Single protein encapsulated SN38 for tumor-targeting treatment. Yu C; Huang F; Wang K; Liu M; Chow WA; Ling X; Li F; Causey JL; Huang X; Cook-Wiens G; Cui X J Transl Med; 2023 Dec; 21(1):897. PubMed ID: 38072965 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of novel SN38-glucose conjugate for colorectal cancer treatment. Zhang R; Luo Y; Du C; Wu L; Wang Y; Chen Y; Li S; Jiang X; Xie Y Bioorg Med Chem Lett; 2023 Feb; 81():129128. PubMed ID: 36639036 [TBL] [Abstract][Full Text] [Related]
6. Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines. Takahata T; Ookawa K; Suto K; Tanaka M; Yano H; Nakashima O; Kojiro M; Tamura Y; Tateishi T; Sakata Y; Fukuda S Basic Clin Pharmacol Toxicol; 2008 Apr; 102(4):399-407. PubMed ID: 18248513 [TBL] [Abstract][Full Text] [Related]
7. ATP citrate lyase mediates resistance of colorectal cancer cells to SN38. Zhou Y; Bollu LR; Tozzi F; Ye X; Bhattacharya R; Gao G; Dupre E; Xia L; Lu J; Fan F; Bellister S; Ellis LM; Weihua Z Mol Cancer Ther; 2013 Dec; 12(12):2782-91. PubMed ID: 24132143 [TBL] [Abstract][Full Text] [Related]
8. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Allen JD; van Loevezijn A; Lakhai JM; van der Valk M; van Tellingen O; Reid G; Schellens JH; Koomen GJ; Schinkel AH Mol Cancer Ther; 2002 Apr; 1(6):417-25. PubMed ID: 12477054 [TBL] [Abstract][Full Text] [Related]
9. Novel disulfide bond bridged 7-ethyl-10-hydroxyl camptothecin-undecanoic acid conjugate/human serum albumin nanoparticles for breast cancer therapy. Zhang Y; Wang J; Liu C; Xing H; Jiang Y; Li X J Mater Chem B; 2023 Mar; 11(11):2478-2489. PubMed ID: 36843543 [TBL] [Abstract][Full Text] [Related]
10. Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells. Ishikawa T; Ikegami Y; Sano K; Nakagawa H; Sawada S Curr Pharm Des; 2006; 12(3):313-25. PubMed ID: 16454746 [TBL] [Abstract][Full Text] [Related]
11. Lipid nanoparticles loaded with 7-ethyl-10-hydroxycamptothecin-phospholipid complex: in vitro and in vivo studies. Liu H; Lu H; Liao L; Zhang X; Gong T; Zhang Z Drug Deliv; 2015; 22(6):701-9. PubMed ID: 24625262 [TBL] [Abstract][Full Text] [Related]
12. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Candeil L; Gourdier I; Peyron D; Vezzio N; Copois V; Bibeau F; Orsetti B; Scheffer GL; Ychou M; Khan QA; Pommier Y; Pau B; Martineau P; Del Rio M Int J Cancer; 2004 May; 109(6):848-54. PubMed ID: 15027118 [TBL] [Abstract][Full Text] [Related]
13. Hydrophobized SN38 to redox-hypersensitive nanorods for cancer therapy. Zheng Y; Yan X; Wang Y; Duan X; Wang X; Chen C; Tian D; Luo Z; Zhang Z; Zeng Y J Mater Chem B; 2019 Jan; 7(2):265-276. PubMed ID: 32254551 [TBL] [Abstract][Full Text] [Related]
14. Solid lipid nanoparticles containing 7-ethyl-10-hydroxycamptothecin (SN38): Preparation, characterization, in vitro, and in vivo evaluations. Mosallaei N; Mahmoudi A; Ghandehari H; Yellepeddi VK; Jaafari MR; Malaekeh-Nikouei B Eur J Pharm Biopharm; 2016 Jul; 104():42-50. PubMed ID: 27108266 [TBL] [Abstract][Full Text] [Related]
15. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo. Yamazaki R; Nishiyama Y; Furuta T; Hatano H; Igarashi Y; Asakawa N; Kodaira H; Takahashi H; Aiyama R; Matsuzaki T; Yagi N; Sugimoto Y Mol Cancer Ther; 2011 Jul; 10(7):1252-63. PubMed ID: 21566063 [TBL] [Abstract][Full Text] [Related]
18. Novel Hydrophilic Camptothecin Derivatives Conjugated to Branched Glycerol Trimer Suppress Tumor Growth without Causing Diarrhea in Murine Xenograft Models of Human Lung Cancer. Tsuchihashi Y; Abe S; Miyamoto L; Tsunematsu H; Izumi T; Hatano A; Okuno H; Yamane M; Yasuoka T; Ikeda Y; Tsuchiya K Mol Pharm; 2020 Apr; 17(4):1049-1058. PubMed ID: 32068412 [TBL] [Abstract][Full Text] [Related]
19. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6. Ishii M; Iwahana M; Mitsui I; Minami M; Imagawa S; Tohgo A; Ejima A Anticancer Drugs; 2000 Jun; 11(5):353-62. PubMed ID: 10912951 [TBL] [Abstract][Full Text] [Related]
20. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11. Mishra MN; Vangara KK; Palakurthi S Anticancer Res; 2014 Nov; 34(11):6345-51. PubMed ID: 25368234 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]